Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABvac40 in mild to moderate Alzheimer's disease
NCT03113812Phase 1Completed
- Sponsor
- Araclon Biotech
- Start
- Jan 2014
- Primary completion
- Jul 2015
- Modality
- Peptide-based Cancer Vaccines
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing ABvac40 with Placebo (2 arms). Primary endpoint: Number of participants with adverse events. Started Jan 2014; status: completed.
02
Drugs
ABvac40
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03113812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03113812.